Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vB_EcoM-A7
- Development stage
- Preclinical
01
Overview
vB_EcoM-A7 is a lytic bacteriophage (specifically a Myoviridae coliphage) that targets and lyses susceptible *Escherichia coli* isolates, including drug-resistant strains. It is utilized as a therapeutic adjunct matched to specific patient bacterial isolates via computational platforms, such as the one developed by Precise Health. The phage functions by binding to specific receptors on the surface of *E. coli*, injecting its double-stranded DNA, replicating within the host, and ultimately lysing the bacterial cell to release progeny virions. This lytic action helps to reduce the bacterial load and can work synergistically with antibiotics to overcome resistance.
- Other names
- Escherichia phage vB_EcoM-A7vB_EcoM-A7 phage
Beyond the preview
Go deeper on vB_EcoM-A7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vB_EcoM-A7.